| Molly S Stumacher, MD | |
|
440 E Marshall St, Ste 201, West Chester, PA 19380 | |
| (610) 738-2500 | |
| (610) 738-2540 |
| Full Name | Molly S Stumacher |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 24 Years |
| Location | 440 E Marshall St, West Chester, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396842126 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD423066 (Pennsylvania) | Primary |
| 174400000X | Specialist | MD423066 (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Main Line Health Home Care & Hospice - Home Health | Radnor, PA | Home health agency |
| Main Line Health Homecare & Hospice - Hospice | Radnor, PA | Hospice |
| Bryn Mawr Hospital | Bryn mawr, PA | Hospital |
| Main Line Hospital Lankenau | Wynnewood, PA | Hospital |
| Paoli Hospital | Paoli, PA | Hospital |
| Riddle Memorial Hospital | Media, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bryn Mawr Medical Specialists Association | 4183610934 | 94 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.
A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.
› Verified 2 days ago
| Entity Name | Bryn Mawr Medical Specialists Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841226099 PECOS PAC ID: 4183610934 Enrollment ID: O20040426000467 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.
A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.
› Verified 2 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679677975 PECOS PAC ID: 6204730955 Enrollment ID: O20150221000231 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.
A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Molly S Stumacher, MD 440 E Marshall St, Ste 201, West Chester, PA 19380 Ph: (610) 738-2500 | Molly S Stumacher, MD 440 E Marshall St, Ste 201, West Chester, PA 19380 Ph: (610) 738-2500 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.
A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.
Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.
› Verified 2 days ago
Dr. Amy Chang, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 520 Maple Ave, Ste 3, West Chester, PA 19380 Phone: 484-364-2824 Fax: 610-350-3099 | |
Christopher L Baldi, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 915 Old Fern Hill Rd, Bldg. A Suite 5, West Chester, PA 19380 Phone: 610-696-2850 Fax: 610-696-7159 | |
Dr. Gary Richard Peters, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1235 Great Oak Cir, West Chester, PA 19380 Phone: 610-431-7430 | |
Mr. Vinod Kumar Kataria, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 529 Maple Ave, West Chester, PA 19380 Phone: 610-344-7370 Fax: 610-344-7080 | |
Dr. David E Bobman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 915 Old Fern Hill Road, Building B Suite 300, West Chester, PA 19380 Phone: 610-431-3122 Fax: 610-431-4799 | |
Dr. Andrew D Sitkoff, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 839 Lincoln Ave Ste A, West Chester, PA 19380 Phone: 610-241-3050 Fax: 610-241-3059 | |
Cheryl A Johnson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 440 E Marshall St, Ste 201, West Chester, PA 19380 Phone: 610-738-2500 Fax: 610-738-2540 |